Synthetic Blood International, Inc. recently announced that preliminary laboratory and animal studies on its implantable glucose biosensor appear to be positive enough to result in long-term implant studies in animals.
The sensor, called Beta, is a battery-operated glucose detector which is smaller than a cardiac pacemaker. The device would be implanted under the skin or in the abdomen, drawing oxygen from surrounding tissue in order to refuel the sensor for continuous monitoring.
Recent tests conducted at the Charles Kettering Laboratories in Yellow Springs, Ohio, appear to confirm that Synthetic Blood International may have solved many of the problems common with such devices, including membrane bio-compatibility, implant life and accuracy of glucose readings with low oxygen concentration. The company believes that the Beta’s accuracy rate of plus or minus five percent is unmatched by other such sensors.
Said Roger A. Ekbom, chief executive officer of Synthetic Blood International, “A primary goal is extending the battery life. Our recent implanted temperature probe studies indicate we have an extended battery life of more than four months. We believe that with this new technology, we should be able to lengthen the implant life to more than one year and still achieve accurate readings as frequently as every seven minutes.”